Abstract 5349
Background
ARTEMIS (A Randomized, TNBC Enrolling trial to confirm Molecular profiling Improves Survival) is a randomized trial to determine if precision guided neoadjuvant chemotherapy (NACT) impacts rates of pathologic complete response in the breast and axillary nodes (pCR). We hypothesized that CTCs in peripheral blood at the time of surgery, after completion of NACT, would be prognostic in TNBC.
Methods
Venous Blood taken following completion of NACT and immediately prior to surgery was assessed for CTCs after NACT as part of two IRB approved studies, ARTEMIS (2014 – 0185/PA15-1050) and LAB04-0698. CTCs (per 7.5 ml blood) were identified using the Cell Search® System (Menarini Silicon Biosystems). Samples with one or more cells having morphologic criteria for malignancy were deemed CTC+. Log-rank test and Cox regression analysis were applied to evaluate associations between CTC+, pCR, and overall survival.
Results
pCR was achieved in 24/68 (35%) patients with TNBC. Twenty four patients (35%) were CTC+. 3 year overall survival was evaluated in 4 groups of patients: pCR-no CTCs (n = 20), pCR-CTC + (n = 4), non-pCR-no CTCs (n = 24) and non-pCR-CTC + (n = 20). Three year OS was higher in the pCR-no CTCs cohort (100%), compared to pCR-CTC + (50%), non-pCR-no CTCs (83%), non-pCR-CTC + (19%); log rank p < 0.0001. In this data set, the presence of CTCs was associated with significant risk of death at 3 years [hazard ratio of 12.3 (95% CI 3.4-454, p = 0.00002)], whereas a favorable, but non-significant trend was noted for pCR [hazard ratio of 0.2 (95% CI 0.0, 1.4, p = 0.11)].
Conclusions
The presence of CTCs at the time of surgery after NACT has prognostic significance beyond that of pCR and should be considered in evaluation of patients for adjuvant clinical trials.
Clinical trial identification
Legal entity responsible for the study
University of Texas, MD Anderson.
Funding
University of Texas, MD Anderson.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4942 - Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer
Presenter: Tony Loughman
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5641 - Comparing the prognosis of favourable-histology breast cancers between younger women of less than 45 years of age at diagnosis with their older counterparts.
Presenter: Guek Eng Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4448 - TNBC universe: a monocentric retrospective analyses of TILs and AR as prognostic markers
Presenter: Agnese Losurdo
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4755 - Genomic spectrum of Asian breast cancer based on targeted next-generation sequencing in 150 consecutive primary breast cancer
Presenter: Chihwan Cha
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2741 - The Impact of the 21 Gene Recurrence Score (RS) on Chemotherapy (CHemoRx) Prescribing in Hormone Receptor (HR) Positive, Lymph Node Positive (LN+) Early-Stage Breast Cancer (BC) in Ireland: A National, Multi-centre, Prospective Study (CTRIAL-IE 15-34)
Presenter: Anees Hassan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3356 - Lymphocyte-predominant breast cancer has a significant lower mean of absolute neutrophil counts compared to non-lymphocyte-predominant breast cancer: Analyses with 576 cases
Presenter: Da Young Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4020 - Genetic Alterations of Early-Stage Breast Cancers by next-generation sequencing (NGS)
Presenter: Yan Xu
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4924 - Oncotype Dx results in patients _40 years, Does age matters?: new insights
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2646 - Impact of BRCA status on outcomes and survival in high-risk early breast cancers
Presenter: Elodie Klajer
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4516 - Early breast cancer classified as intermediate risk by the Prosigna assay: Characteristics and treatment strategy
Presenter: Nawale Hajjaji
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract